rs104886003
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Disruption of the IRS1-p110α E545K interaction destabilizes the p110α protein, reduces AKT phosphorylation, and slows xenograft tumor growth of a cancer cell line expressing p110α E545K.
|
23643389 |
2013 |
rs2699887
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Epidemiologic studies suggested that mutations of the PI3K/PTEN/AKT pathway genes are associated with cancer risk, yet no data are available for PTEN rs701848, PIK3CA rs2699887, and AKT1 rs2494752 polymorphism and breast cancer(BC) risk.
|
28423632 |
2017 |
rs104886003
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Expression of Pik3ca with E545K mutation alone was unable to cause hyperplasia or cancer in the uterus and did not activate Akt as effectively as Pten deletion in short-term cultures of mouse endometrial epithelium, likely explaining the lack of phenotype in vivo.
|
25698082 |
2015 |
rs121913279
|
|
|
0.080 |
GeneticVariation |
BEFREE |
One EBV-positive cancer with PIK3CA mutation (H1047R) was MSI-positive.
|
23236232 |
2012 |
rs121913279
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Our results define a key effect of PIK3CA(H1047R) on mammary cell fate in the pre-neoplastic mammary gland and show that the cell of origin of PIK3CA(H1047R) tumours dictates their malignancy, thus revealing a mechanism underlying tumour heterogeneity and aggressiveness.
|
26266975 |
2015 |
rs121913279
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Since the PI3Kα isoform is implicated mostly in cancer, we conducted a high-throughput screening (HTS) campaign using a 3-step PI3K homogenous time-resolved fluorescence assay against this isoform bearing the H1047R mutation.
|
29991713 |
2018 |
rs121913279
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The cell proliferation and migration of cancer cells bearing H1047R mutation were also reduced by P6-55.
|
28743532 |
2017 |
rs121913279
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The sequencing identified two hotspot mutations in exon 20 of one cancer samples at p. H1047L (c. 3140A > T) and eight cancer sample at p. H1047R (c. 3140A > G).
|
28269754 |
2017 |
rs778184105
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This combination treatment ultimately leads to the expansion of cancer progenitors with a PTEN E91D mutation, suggesting that the analysis of PTEN mutations could predict therapeutic response to the dual therapy.
|
21138868 |
2010 |
rs104886003
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This study offers evidence that personalizing treatment of ER-positive breast cancers to PI3K inhibitor therapy may benefit from an analysis of PIK3CA-E545K-AKT1-estrogen signaling pathways.Cancer Res; 76(13); 3989-4001.©2016 AACR.
|
27197157 |
2016 |
rs121913279
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Understanding how the H1047R mutation causes the enhanced activity of the protein in atomic detail is central to developing mutant-specific therapeutics for cancer.
|
25340423 |
2014 |
rs121913279
|
|
|
0.080 |
GeneticVariation |
BEFREE |
We developed a sensitive, simple and rapid approach to detect the low-abundance PIK3CA (H1047R) mutation in real CRC specimens, providing an effective tool for guiding cancer targeted therapy.
|
27405731 |
2016 |
rs121913279
|
|
|
0.080 |
GeneticVariation |
BEFREE |
We performed exome sequencing of DNA from unaffected and affected cells from an individual with an unclassified syndrome of congenital progressive segmental overgrowth of fibrous and adipose tissue and bone and identified the cancer-associated mutation encoding p.His1047Leu in PIK3CA, the gene that encodes the p110α catalytic subunit of PI3K, only in affected cells.
|
22729222 |
2012 |